Neoadjuvant FOLFOX, with Selective Active Use of Combined Modality Advance rectal ca stage ii and None iii Chemoradiation versus Preoperative Combined Modality Chemoradiation Gastric Cancer Trial # Diagnosis Schema Drugs Provided Status METASTATIC GASTRIC TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) TAS-102-302 TAS-102 **NEW** CANCER REFRACTORY TO Vs PLACEBO PLUS BSC STANDARD TREATMENTS Leukemia Trial # Treatment Schema Drugs Provided Status A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Untreated CLL in younger Fludarabine, Cyclophosphamide, and Ibrutinib patients ***NEW*** Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) Newly Diagnosed A Phase III Randomized Trial of Blinatumomab & IV Blinatumomab for Newly Diagnosed E1910 B Lineage Acute ***NEW*** Solution Stabilizer for B Lineage Acute Lymphoblastic Leukemia in Blinatumomab (AMG Lymphoblastic Leukemia in Adults Adults 103)
Advance rectal ca stage ii and iii Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation None Active Gastric Cancer Trial # Diagnosis Schema Drugs Provided Status TAS-102-302 METASTATIC GASTRIC CANCER REFRACTORY TO STANDARD TREATMENTS TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) Vs PLACEBO PLUS BSC TAS-102 **NEW** Leukemia Trial # Treatment Schema Drugs Provided Status Untreated CLL in younger patients A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) Ibrutinib ***NEW*** E1910 Newly Diagnosed B Lineage Acute Lymphoblastic Leukemia in Adults A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed B Lineage Acute Lymphoblastic Leukemia in Adults Blinatumomab & IV Solution Stabilizer for Blinatumomab (AMG 103) ***NEW***